Shares of Alkermes ALKS were unchanged after the company reported Q2 results.
Quarterly Results
Earnings per share rose 400.00% over the past year to $0.30, which beat the estimate of $0.12.
Revenue of $303,717,000 rose by 22.70% year over year, which beat the estimate of $278,700,000.
Guidance
Alkermes raised FY21 adjusted EPS guidance from $0.37-$0.62 to $0.52-$0.70.
The company also boosted sales forecast from $1.1 billion-$1.17 billion to $1.145 billion-$1.185 billion.
Conference Call Details
Date: Jul 28, 2021
Time: 08:00 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/4e3wudx6
Recent Stock Performance
52-week high: $25.74
Company's 52-week low was at $15.35
Price action over last quarter: Up 10.84%
Company Description
Alkermes PLC is a fully integrated global biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in major therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, to access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
